120 related articles for article (PubMed ID: 6124583)
21. Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.
Niznik HB; Grigoriadis DE; Pri-Bar I; Buchman O; Seeman P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):333-43. PubMed ID: 2863760
[TBL] [Abstract][Full Text] [Related]
22. Sodium ion modulates D2 receptor characteristics of dopamine agonist and antagonist binding sites in striatum and retina.
Makman MH; Dvorkin B; Klein PN
Proc Natl Acad Sci U S A; 1982 Jul; 79(13):4212-6. PubMed ID: 6213964
[TBL] [Abstract][Full Text] [Related]
23. Complete conversion of brain D2 dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide.
Grigoriadis D; Seeman P
J Neurochem; 1985 Jun; 44(6):1925-35. PubMed ID: 3157782
[TBL] [Abstract][Full Text] [Related]
24. [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalen (ADTN). Regional distribution and in vivo binding after acute and chronic drug treatment.
Clement-Cormier Y; Smith CE
Neurochem Res; 1980 Jun; 5(6):641-51. PubMed ID: 7402434
[TBL] [Abstract][Full Text] [Related]
25. Binding sites for [3H]SCH 23390 in retina: properties and possible relationship to dopamine D1-receptors mediating stimulation of adenylate cyclase.
Makman MH; Dvorkin B
Brain Res; 1986 Dec; 387(3):261-70. PubMed ID: 2950967
[TBL] [Abstract][Full Text] [Related]
26. 3H-(-)DO 710 discriminates guanine nucleotide sensitive and insensitive dopamine binding sites.
Sokoloff P; Redouane K; Brann M; Martres MP; Schwartz JC
Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):236-43. PubMed ID: 4022135
[TBL] [Abstract][Full Text] [Related]
27. Selective labeling of apomorphine receptors by 3H-LSD.
Whitaker PM; Seeman P
Eur J Pharmacol; 1979 Jun; 56(3):269-71. PubMed ID: 225177
[TBL] [Abstract][Full Text] [Related]
28. Identification of D3 and sigma receptors in the rat striatum and nucleus accumbens using (+/-)-7-hydroxy-N,N-di-n-[3H]propyl-2-aminotetralin and carbetapentane.
Wallace DR; Booze RM
J Neurochem; 1995 Feb; 64(2):700-10. PubMed ID: 7830063
[TBL] [Abstract][Full Text] [Related]
29. Effects of ADTN and various other 2-aminotetralin derivatives on the efflux of 3H-dopamine from rat striatal slices.
Mulder AH; Braakhuis B; De Regt V; Dijkstra D; Horn AS
Eur J Pharmacol; 1980 Jun; 64(4):349-55. PubMed ID: 7389827
[TBL] [Abstract][Full Text] [Related]
30. Dopamine receptor mediated inhibition by pergolide of electrically-evoked 3H-dopamine release from striatal slices of cat and rat: slight effect of ascorbate.
Lehmann J; Arbilla S; Langer SZ
Naunyn Schmiedebergs Arch Pharmacol; 1981 Aug; 317(1):31-5. PubMed ID: 7279007
[TBL] [Abstract][Full Text] [Related]
31. Interaction of the putative dopamine autoreceptor agonists 3-PPP and TL-99 with [3H]apomorphine binding sites in rat striatal membranes.
Williams M; Totaro JA
Eur J Pharmacol; 1982 Dec; 86(1):35-42. PubMed ID: 7160432
[TBL] [Abstract][Full Text] [Related]
32. Retina contains guanine nucleotide sensitive and insensitive classes of dopamine receptors.
Makman MH; Dvorkin B; Horowitz SG; Thal LJ
Eur J Pharmacol; 1980 May; 63(2-3):217-22. PubMed ID: 6155277
[TBL] [Abstract][Full Text] [Related]
33. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
Leff SE; Creese I
Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
[TBL] [Abstract][Full Text] [Related]
34. Reduced dopaminergic binding during aging in the rodent striatum.
Severson JA; Finch CE
Brain Res; 1980 Jun; 192(1):147-62. PubMed ID: 6155174
[TBL] [Abstract][Full Text] [Related]
35. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes.
Hamblin MW; Creese I
Mol Pharmacol; 1982 Jan; 21(1):44-51. PubMed ID: 6127621
[TBL] [Abstract][Full Text] [Related]
36. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.
Fuxe K; Agnati LF; Köhler C; Kuonen D; Ogren SO; Andersson K; Hökfelt T
J Neural Transm; 1981; 51(1-2):3-37. PubMed ID: 7264628
[TBL] [Abstract][Full Text] [Related]
37. Chronic D-amphetamine and phencyclidine: effects on dopamine agonist and antagonist binding sites in the extrapyramidal and mesolimbic systems.
Robertson HA
Brain Res; 1983 May; 267(1):179-82. PubMed ID: 6860944
[TBL] [Abstract][Full Text] [Related]
38. S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.
Rollema H; Feenstra MG; Grol CJ; Lewis MH; Staples L; Mailman RB
Naunyn Schmiedebergs Arch Pharmacol; 1986 Apr; 332(4):338-45. PubMed ID: 3736679
[TBL] [Abstract][Full Text] [Related]
39. Solubilized receptors for [3H]dopamine (D3 binding sites) from canine brain.
Davis A; Madras BK; Seeman P
Biochem Pharmacol; 1982 Apr; 31(7):1183-7. PubMed ID: 7092913
[TBL] [Abstract][Full Text] [Related]
40. Characterization of unique ADTN-catecholamine binding sites in the iris root-ciliary body of rabbits.
Rohde BH; Chiou GC
Curr Eye Res; 1989 Dec; 8(12):1225-31. PubMed ID: 2560692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
